当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Infant Consequences and Procedures in Mammary Cancer during Pregnancy

Senneby J

Breast cancer is a common type of cancer diagnosed during pregnancy, and its incidence has increased in recent years as more women choose to delay childbirth. Compared with breast cancer in the general population, pregnancy-associated breast cancer (PABC) is significantly different in terms of epidemiology, diagnosis, and treatment management, yet exhibits particularly aggressive behavior due to its unique molecular and biological profile.Although not fully understood, the pathophysiological basis of PABC may result from a combination of hormonal and immunological changes, breast regression, and gene expression changes during pregnancy. There is considerable controversy in the existing literature regarding the impact of PABC on pregnancy outcomes, both in terms of short-term and long-term effects on maternal and fetal/neonatal health. The majority of patients with PABC have advanced disease when first diagnosed, poor survival, and a significantly poor prognosis. Although the most commonly reported obstetricfetal adverse events are prematurity and prematurity-related neonatal morbidity, other treatment-related neonatal complications are common even when safe treatment options are used during pregnancy. The aim of the current comprehensive review is to summarize current knowledge and understanding of the pathophysiological, molecular, and biological basis of PABC and its association with adverse maternal, obstetric, fetal, and neonatal outcomes.